Abstracts tagged "Tumor necrosis factor (TNF)"

Abstract Number: 0204 • ACR Convergence 2021
Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents
Soo Min Ahn¹, Jonggi Choi², Byong Duk Ye², Suk-Kyun Yang², Ji Seon Oh³, Yong-Gil Kim², Chang-Keun Lee², Bin Yoo¹, Sang Hyoung Park² and Seokchan Hong², ¹ASAN MEDICAL CENTER, Seoul, South Korea, ²Asan Medical Center, Seoul, Republic of Korea, ³Asan Medical Center, Ulsan, Republic of Korea
Background/Purpose: Prophylactic anti-viral therapy is required in patients with hepatitis B virus (HBV) infection receiving biologics because of the high risk of HBV reactivation. However,…
Abstract Number: 0246 • ACR Convergence 2021
Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs
Betul Sozeri¹, Kenan Barut², Erdal Atalay³, Aysenur Pac Kisaarslan⁴, Semanur Ozdel⁵, Ozge Altug⁶, Ferhat Demir¹, Balahan Makay⁷, Nuray Aktay Ayaz⁸, Ersen Acar⁹, Fatih Haslak², Erdal Sag¹⁰, Mehmet YILDIZ², Ummusen Kaya Akca¹⁰, Amra Adrovic², Yelda Bilginer¹⁰, Hakan Poyrazoglu¹¹, Erbil Unsal⁷, Ozgur Kasapcopur¹² and Seza Ozen³, ¹University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ³Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey, ⁴Erciyes University Medical Faculty, Pediatric Rheumatology, Kayeri, Turkey, ⁵Ankara Dr.Sami Ulus Gynecology and Pediatrics Research and Training Hospital, Pediatric Rheumatology, Ankara, Turkey, ⁶Dr Behcet Uz Children's Hospital, Pediatric Rheumatology, Izmir, Turkey, ⁷Dokuz Eylul University Faculty of Medicine, Pediatric Rheumatology, Izmir, Turkey, ⁸Istanbul University, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ⁹Novartis, Istanbul, Turkey, ¹⁰Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ¹¹Erciyes University Faculty of Medicine, Pediatric Rheumatology, Kayseri, Turkey, ¹²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is the most acute and severe form of JIA. Despite the substantial evidence supporting the effectiveness of biologic drugs…
Abstract Number: 0451 • ACR Convergence 2021
Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
Murat Torgutalp¹, Valeria Rios Rodriguez¹, Maryna Verba², Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Hildrun Haibel³, Martin Rudwaleit⁴, Joachim Sieper³ and Denis Poddubnyy⁵, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁵Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Observational cohort studies have shown that there is low, but still detectable progression level in radiographic sacroiliitis, which might also have an impact on…
Abstract Number: 0511 • ACR Convergence 2021
Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B
Jorge Romo-Tena¹, Jose Esparza-Lopez², Carmelo Carmona-Rivera³, Luz P blanco³, Mariana Kaplan⁴ and María de Jesús Ibarra-Sánchez², ¹INNSZ / NIAMS, Mexico City, Mexico, ²INNSZ, Mexico City, Mexico, ³NIAMS, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD
Background/Purpose: Endothelial dysfunction is a hallmark in the pathogenesis of many inflammatory diseases. The endothelial-to-mesenchymal transition (EndoMT) is a process where endothelial cells lose their…
Abstract Number: 0514 • ACR Convergence 2021
Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel¹, Anil singh¹, Judy Vinh¹, H. Mark Kenney², Edward Schwarz³, David Fox⁴, Sadik Khuder⁵ and Salah-uddin Ahmed¹, ¹Washington State University, Spokane, WA, ²University of Rochester Medical Center, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Department of Medicine and Public Health, University of Toledo,, Toledo, OH
Background/Purpose: TNF-α drives RA synovial fibroblast (RASF)-mediated hyperplasia and joint tissue destruction. Extracellular sulfatase-2 (Sulf-2) influences receptor/ligand binding and subsequent signaling of chemokines, cytokines, and…
Abstract Number: 0515 • ACR Convergence 2021
The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel, Sang Han and Salah-uddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Recent unpublished findings from our lab show that the extracellular enzyme sulfatase-2 (Sulf-2) facilitates pro-inflammatory TNF-α signaling which activates rheumatoid arthritis synovial fibroblasts (RASFs).…
Abstract Number: 0527 • ACR Convergence 2021
Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro
Anil singh, farheen Shaikh and Salah-uddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Terminal uridylyl transferase 7 (TUT7), also known as Zcchc6, is a zinc finger domain-containing protein responsible for terminal uridylation of miRNA, implicated in pre-miRNA…
Abstract Number: 0931 • ACR Convergence 2021
Early Improvement in Disease Activity Indices Predicts Achievement of Long-term Clinical Remissions, ASDAS Inactive Disease and Low BASDAI with Normal CRP, During TNF-α-inhibitor Therapy in Patients with Ankylosing Spondylitis
Sang Jin Lee, Na Ri Kim and Eon Nam, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea
Background/Purpose: As biologic agents including tumor necrosis factor (TNF)-α inhibitors (TNFi) have been proven to improve enormously clinical outcomes for patients with ankylosing spondylitis (AS),…
Abstract Number: 0947 • ACR Convergence 2021
Cytokine Competent Gut-joint Migratory T Cells Contribute to Inflammation in the Joint
Adam Lefferts¹, David Claypool¹, Eric Norman¹, Uma Kantheti¹ and Kristine Kuhn², ¹University of Colorado, Anschutz Medical Campus, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Although studies have identified the presence of gut-associated cells in the enthesis of joints affected by spondyloarthritis, a direct link through cellular transit between…
Abstract Number: 0978 • ACR Convergence 2021
Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin
Amer Khojah¹, Gabrielle Morgan² and Lauren Pachman³, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Neopterin is a metabolic product of guanosine triphosphate, which is produced by macrophages upon stimulation with interferon-gamma from activated T helper cells. Despite the…
Abstract Number: 1016 • ACR Convergence 2021
Assessment of Pre-Inflammatory Mesenchymal (PRIME) Cells as a Biomarker of Tumor Necrosis Factor-Induced Arthritis in Mice
Kiana Chen¹, Xi Lin¹, Lianping Xing², H. Mark Kenney³, Richard Bell⁴, Edward Schwarz⁵ and Homaira Rahimi⁵, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester Medical Center, Webster, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵University of Rochester, Rochester, NY
Background/Purpose: Recently, CD45−CD31−Podoplanin (PDPN)+ synovial fibroblast-like cells, termed pre-inflammatory mesenchymal (PRIME) cells were found to be differentially expressed and circulate in the blood of rheumatoid…
Abstract Number: 1497 • ACR Convergence 2020
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Bonnie Bermas¹, Megan Clowse², Milena Gianfrancesco³, Jonathan Hausmann⁴, Pedro M Machado⁵, Emily Sirotich⁶, Helen Robinson⁷, Anja Strangfeld⁸, Jinoos Yazdany⁹ and Philip Robinson¹⁰, ¹UTSouthwestern.edu, Dallas, TX, ²Duke University, Chapel Hill, NC, ³University of California, San Francisco, San Francisco, CA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵University College London, London, United Kingdom, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Queensland School of Medicine, HERSTON, Queensland, Australia, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹UCSF, San Francisco, CA, ¹⁰University of Queensland, Herston, Queensland, Australia
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…
Abstract Number: 1895 • ACR Convergence 2020
Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
Maria Llop¹, Mireia Moreno², Jordi Gratacós³, Victoria Navarro-Compán⁴, Eugenio De Miguel⁵, Pilar Font⁶, Teresa Clavaguera⁷, Luis Francisco Linares⁸, Beatriz Joven⁹ and Xavier Juanola¹⁰, ¹Hospital Universitari Parc Taulí I3PT, Sabadell, Catalonia, Spain, ²Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁴Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁷Hospital Universitari Trueta, Girona, Spain, ⁸Hospital de la Arrixaca, Murcia, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Clinical efficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA) has been widely probed in randomized control trials. In clinical practice, some studies suggested…
Abstract Number: 2022 • ACR Convergence 2020
Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – Results from a Prospective Study Using PET-MRI of SIJ and Spine
Xenofon Baraliakos¹, Styliani Tsiami², Christoph Rischpler³, Nils-Martin Bruckmann⁴, Wolfgang Fendler³, Julian Kirchner⁵, Ken Herrmann³, Lino Morris Sawicki⁵ and Juergen Braun⁶, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Department of Nuclear Medicine, University Essen-Duisburg, Essen, Germany, ⁴Department of Radiology, University Duesseldorf, Düsseldorf, Germany, ⁵Department of Radiology, University Duesseldorf, Duesseldorf, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany
Background/Purpose: The clinical efficacy of TNFi in patients with axSpA is well established but its effect on new bone formation is still unclear. Positron emission…
Abstract Number: 0507 • ACR Convergence 2020
Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study
Grace Wright¹, Peter Nash², Laura Coates³, Jordi Gratacós⁴, Frank Behrens⁵, Kevin Ding⁶, Weibin Bao⁷, Luminita Pricop⁶, Corine Gaillez⁸ and Iain McInnes⁹, ¹Association of Women in Rheumatology, New York, NY, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Oxford, Oxford, United Kingdom, ⁴University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁵CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁶Novartis Pharmaceuticals Corporation, East Hanover, ⁷Novartis Pharmaceuticals Corporation, East Hannover, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries.1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].